Oncolys BioPharma Inc.
JPX: 4588.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yasuo Urata
- Employees
- 40
- Headquarters
- Tokyo, Japan
- IPO year
- 2013
- Market cap
- ¥72.5B
- Website
- https://www.oncolys.com
Loading 4588…
Loading profile data…Frequently asked questions about 4588
What does Oncolys BioPharma Inc. (4588.T) do?
Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatm...
Where does 4588.T trade?
Oncolys BioPharma Inc. (4588.T) trades on the Tokyo Stock Exchange.
What sector is 4588.T in?
Oncolys BioPharma Inc. (4588.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oncolys BioPharma Inc.?
Yasuo Urata is the chief executive officer of Oncolys BioPharma Inc. (4588.T).
Where is Oncolys BioPharma Inc. headquartered?
Oncolys BioPharma Inc. is headquartered in Japan.
Does 4588.T pay a dividend?
Oncolys BioPharma Inc. (4588.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4588.T go public?
Oncolys BioPharma Inc. (4588.T) completed its initial public offering in 2013.